VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards
26 sept. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
25 sept. 2018 08h00 HE
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationIntermediate-dose study arm: enrollment complete Initial immunologic data from low...
VBI Vaccines Responds to Unfounded Allegations in Globes Article
16 sept. 2018 01h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
VBI Vaccines Responds to Unfounded Allegations in Globes Article
16 sept. 2018 01h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
28 août 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
15 août 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as...
VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference
06 août 2018 16h15 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update
26 juil. 2018 07h00 HE
|
VBI Vaccines, Inc.
-- Pivotal Phase 3 program for Sci-B-Vac® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019 -- -- Positive safety and immunogenicity data from Phase 1 study of...
VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit
09 juil. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference
19 juin 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...